Simon Hayward
Last active: 2/19/2015

Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation.

Dahiya R, Zhang DY, Ho RJ, Haughney PC, Hayward SW, Cunha GR, Narayan P
Biochem Mol Biol Int. 1995 35 (3): 487-98

PMID: 7773185

The present study was designed to investigate the effects of 13-cis-retinoic acid (13-cis-RA) (100 micrograms/mouse/day) and androgen ablation (castration) alone and in combination on growth of a human prostatic carcinoma line (LNCaP) transplanted to athymic nude mice as an experimental model. The results of these studies suggest that; (1) androgen ablation (castration) significantly decreased the size of LNCaP xenograft as compared to untreated animals; (2) when 13-cis-RA was administered to nude mice carrying established tumors (0.51 +/- 0.04 cm3), the tumor size was significantly reduced as compared to untreated controls (0.65 +/- 0.06 cm3 versus 1.63 +/- 0.12 cm3). About 50% of the animals in this group showed xenografts necrosis followed by complete regression of tumors by five months; (3) the combination of androgen ablation and 13-cis-RA treatment to nude mice carrying tumors showed synergistic effect in decreasing the tumor size. These results indicate that combination therapies based on androgen ablation and retinoid administration may be a useful approach for the treatment of prostate cancer.

MeSH Terms (11)

Animals Humans Isotretinoin Male Mice Mice, Nude Necrosis Neoplasm Transplantation Orchiectomy Prostatic Neoplasms Tumor Cells, Cultured

Connections (1)

This publication is referenced by other Labnodes entities: